(Total Views: 367)
Posted On: 10/01/2025 12:56:09 PM
Post# of 157591
Thank you!
I realize some can't/don't get on LinkedIn so here's the full post:
I realize some can't/don't get on LinkedIn so here's the full post:
Quote:
Geoffrey FourqureanGeoffrey Fourqurean
• 3rd+Premium • 3rd+
Neuroscientist, Returned Peace Corps Volunteer, Polyglot, poet, Alumnus: AstraZeneca, GlaxoSmithKline, Neurocrine Biosciences, ex-Gilead, Chief Consultant, Patient Advocate, Biotech Industry Analyst, ESMO Member, AuthorNeuroscientist, Returned Peace Corps Volunteer, Polyglot, poet, Alumnus: AstraZeneca, GlaxoSmithKline, Neurocrine Biosciences, ex-Gilead, Chief Consultant, Patient Advocate, Biotech Industry Analyst, ESMO Member, Author
1d • 1 day ago • Visible to anyone on or off LinkedIn
Follow
A major new review just landed in the *International Journal of Biological Macromolecules* — and it’s a big deal.
Title: **“C–C motif glycoprotein ligand 5 (CCL5) and its GPCR CCR5: Macromolecular game-changers in cancer biology.”**
???? https://lnkd.in/eKZ5MQmK
The paper pulls no punches:
- CCR5 is no longer just an HIV co-receptor.
- The CCL5/CCR5 axis is a **master regulator in oncology**, driving leukocyte recruitment, tumor progression, angiogenesis, metastasis, immune evasion, and therapy resistance.
- Blocking CCR5 is highlighted as a promising therapeutic strategy — with synergy alongside immune checkpoint inhibitors.
Here’s why this matters:
For decades, CCR5 was pigeonholed in infectious disease. Now, peer-reviewed science is validating it as a **macromolecular game-changer in cancer biology**. That is a narrative shift with enormous implications for oncology, immunology, and drug development.
The paper mentions CCR5 antagonists like Maraviroc, Vicriviroc, and Cenicriviroc. But here’s the key: only one CCR5 antagonist has generated broad *human clinical data in oncology and immunotherapy synergy* — **Leronlimab**.
This moment feels like the science is finally catching up to what some of us have been saying for years: CCR5 isn’t a side note. It’s a central node. And it may hold the keys to unlocking new strategies against cancer and immune-driven disease.
The field is wide open. The question now is: who will seize it?
hashtag#CCR5
hashtag#CCL5
hashtag#Oncology
hashtag#Immunotherapy
hashtag#CancerResearch
hashtag#BiotechInnovation
hashtag#TranslationalMedicine
hashtag#OHSU
hashtag#GatesFoundation
hashtag#DARPA
hashtag#BARDA
hashtag#NIH
hashtag#Biopharma
hashtag#GameChanger
hashtag#Macromolecules
(13)
(0)
